Ebdarokimab Injection is characterized by definite efficacy (with a PASI75 response rate of nearly 80% at Week 16 and stable efficacy at Week 52), low incidence of adverse reactions (all<5%), no severe hypersensitivity reactions, and convenient administration.
Authentic
Guarantee
Fast Delivery
Privacy Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



